Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
about
EpCAM in carcinogenesis: the good, the bad or the uglyCODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cellsPhenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancerConstruction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions.EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth.Catumaxomab: in malignant ascites.Monoclonal antibodies therapies for ovarian cancer.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.A survey of treatment approaches of malignant ascites in Germany and Austria.Multiparametric Biomechanical and Biochemical Phenotypic Profiling of Single Cancer Cells Using an Elasticity Microcytometer.Treatment of patients with peritoneal metastases from gastric cancer.
P2860
Q28293163-9DFF5968-C04A-47A6-A84F-5292CCEBC425Q30360904-9C55AEE3-9FDF-4166-AC81-E4BC648783BEQ31149698-018F1384-A0F9-4A3E-845D-1B61C1203AFAQ34461481-76F5F00F-0FB6-4838-8B07-7B6AEBD2C571Q35125662-A502C756-FC74-4687-B44D-67A45B3CBC72Q35556641-74EA6529-C66B-4636-8B2A-5FE4BB8FBEF0Q36772138-3197AC41-6C86-43D2-897C-73E5E5880366Q36985597-73CC0D90-DAB3-4B17-ABE6-E43023EE94E4Q38016957-4904B6F5-A999-4F41-A1CF-9D82D6B1127FQ38078400-77B86266-F205-4A54-8B8A-1BF806469107Q38183786-07D08F1E-6A63-4C32-A794-A040376DC899Q48055525-C9F3062B-67A2-409C-AD94-B8B085089CA8Q50530244-AFF845E5-7C68-4A8C-8488-9BD2E86E6772Q55318427-52E375C8-32E4-44AD-96E2-37415590C973
P2860
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@ast
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@en
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@nl
type
label
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@ast
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@en
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@nl
prefLabel
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@ast
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@en
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@nl
P2860
P1476
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
@en
P2093
Carsten Bokemeyer
P2860
P304
P356
10.1517/14712598.2010.504706
P407
P577
2010-08-01T00:00:00Z